Sacituzumab govitecan: tested on its own
43 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingNCT07299409Phase 2Report a problem
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2Report a problem
- Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)RecruitingNCT06923826Phase 2Report a problem
- Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast CancerRecruitingNCT06665178Phase 2Report a problem
- A Study of Sacituzumab Govitecan in People With MesotheliomaRecruitingNCT06477419Phase 2Report a problem
- Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain MetastasesNot yet recruitingNCT06462079Phase 2Report a problem
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06329869Phase 2Report a problem
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingNCT06263543Phase 2Report a problem
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingNCT06248515Phase 2Report a problem
- Sacituzumab Govitecan in Metastatic Colorectal CancerRecruitingNCT06243393Phase 2/3Report a problem
- HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab GovitecanRecruitingNCT06236269Phase 2Report a problem
- Sacituzumab govitEcan in THYroid CancersRecruitingNCT06235216Phase 2Report a problem
- A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingNCT05838521Phase 2Report a problem
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingNCT05833867Phase 1Report a problem
- Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyRecruitingNCT05770531Phase 2Report a problem
- Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentRecruitingNCT04617522Phase 1Report a problem
- Sacituzumab Govitecan in Recurrent GlioblastomaRecruitingNCT04559230Phase 2Report a problem
- Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerTerminatedNCT05581589Phase 2Results postedReport a problem
- Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05089734Phase 3Results postedReport a problem
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadCompletedNCT04527991Phase 3Results postedReport a problem
- Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziyCompletedNCT04319198Phase 4Results postedReport a problem
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsActive, not recruitingNCT03964727Phase 2Results postedReport a problem
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedNCT03901339Phase 3Results postedReport a problem
- Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed TherapyActive, not recruitingNCT03725761Phase 2Results postedReport a problem
- Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results postedReport a problem
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results postedReport a problem
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)Active, not recruitingNCT06486441Phase 3Report a problem
- Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaActive, not recruitingNCT06178588Phase 2Report a problem
- Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric AdenocarcinomaCompletedNCT06123468Phase 1/2Report a problem
- A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsActive, not recruitingNCT06028932Phase 2Report a problem
- Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersActive, not recruitingNCT05884320Phase 2Report a problem
- Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyActive, not recruitingNCT05840211Phase 3Report a problem
- Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerActive, not recruitingNCT05552001Phase 3Report a problem
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Phase 3Report a problem
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder CancerCompletedNCT05226117Phase 2Report a problem
- Study of Sacituzumab Govitecan in Patients With Solid TumorActive, not recruitingNCT05119907Phase 2Report a problem
- Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsActive, not recruitingNCT05101096Phase 1/2Report a problem
- Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesActive, not recruitingNCT04647916Phase 2Report a problem
- Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingNCT04639986Phase 3Report a problem
- Sacituzumab Govitecan in Primary HER2-negative Breast CancerActive, not recruitingNCT04595565Phase 3Report a problem
- Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsActive, not recruitingNCT04454437Phase 2Report a problem
- A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaActive, not recruitingNCT04251416Phase 2Report a problem
- Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0CompletedNCT03995706Early Phase 1Report a problem